Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics announced promising results from its ADVENT-AML Phase 1B clinical trial, showcasing new clinical and translational data at the Society of Hematology Oncology Annual Meeting. The trial, which focuses on treating relapsed or refractory AML patients with CORE-NK cell therapy in combination with standard AML treatments, reported a 57% clinical response rate among high-risk frontline subjects. The trial has demonstrated safety and efficacy, with no dose-limiting toxicities observed, and is now expanding to include newly diagnosed AML patients who are ineligible for intensive chemotherapy. This development underscores Chimeric’s commitment to advancing cell therapy and could significantly impact treatment options for AML patients.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical-stage company specializing in cell therapy, focusing on developing innovative treatments for cancer. The company has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, aimed at addressing various oncology diseases. Chimeric is recognized for its pioneering work in cell therapy, with assets being developed across multiple clinical programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.02M
See more data about CHM stock on TipRanks’ Stock Analysis page.